Insect production for food & feed, pollination, pest control and research faces critical challenges: natural variable egg output, limited shelf life (~1-2 days), and costly, climate-controlled transport. These constraints hinder adoption, impacting producers, breeders, growers, researchers, and end-users, such as animal farms willing to use insects as live feed and vegetable producers utilizing pollinators or pest control insects. Our solution, StayPrime, revolutionizes insect production by extending larval shelf life to two weeks. StayPrime suspends larval development, creating a buffer against egg variations and reducing reproductive costs. StayPrime also enables cost-effective, regular shipping and storage, eliminating the need for express, climate-controlled transport and enabling storage of live insects at end-user’s sites. By addressing these key limitations, StayPrime unlocks the full potential of insect-based solutions, facilitating integration into large-scale agriculture.

Stazion er en SaaS-platform, der lader salgsteams dele dokumenter med kunder i mapper med indbygget AI Q&A. Vores RAG-baserede chatbot giver modtagere øjeblikkelige svar baseret på dokumenternes indhold, så sælgere slipper for gentagne opfølgninger. Markedet for sales enablement-platforme forventes at nå $12,78 mia. globalt i 2030 (Grand View Research, 2023), og vi adresserer et konkret behov: sælgere bruger op til 30% af deres tid på at besvare dokumentrelaterede spørgsmål manuelt. Stazion demokratiserer adgangen til avanceret AI-teknologi for SMV'er, som typisk ikke har ressourcer til at bygge egne løsninger. Ved at automatisere dokumenthåndtering og vidensdeling frigør vi tid, reducerer fejl og gør kompleks information tilgængelig for alle uanset teknisk niveau. Dette skaber mere effektive salgsprocesser og bedre beslutningsgrundlag for købere. En investering fra Innovationsfonden accelererer udviklingen af vores AI-motor, højere præcision i AI Q&A, samt avanceret analytics der viser sælgere præcis hvilke dokumenter, der driver salg. Midlerne vil også finansiere salg og marketing på det danske og efterfølgende skandinaviske marked. Langsigtet ser vi Stazion som den foretrukne platform for intelligent dokumentdeling i B2B-salg i Norden og derefter Europa. På sigt udvider vi til andre videnstunge brancher, hvor dokumenter skal deles og forstås hurtigt.

Classical drug development is based on proof-of-concept studies using immortalized cell lines and animal models. The use of these non-predictive models has led to high attrition in Phase 1 human clinical trials due to poor clinical safety, toxicity and inappropriate pharmacokinetics. Based on recent discoveries, human stem cell lines can now essentially be instructed to form any tissue type recapitulating 3D architecture and physiology. These predictive 3D models will be a game changer in drug development and significantly reduce the cost of on average USD 1.3 billion for bringing a drug to market. The technical challenges around 3D image-based screens have until now limited their implementation into drug discovery pipelines. Developments in high-content microscopy and image-based analysis are breaking down these barriers. In StemScreen we will establish the first Danish academic-industrial partnership around stem cell-based disease modeling and drug screening with strong international links. Our objective is to establish a network of experts and the infrastructure required to perform high-content phenotypic analyses of stem cell-based 3D models supporting drug discovery and commercialization. Specifically, we will within StemScreen identify lead compounds for at least 7 clinical conditions and advance the methods for stem cell-based 3D models. Collectively, this will push specialist training and bioinnovation in Denmark.

Projektet udvikler en mikrofluidisk impedans flow cytometri?chip med mere end 100 parallelle og integrede målekanaler ved brug af en stencil?baseret fabrikationsmetode. Den øgede væskegennemstrømning giver hurtig, følsom og brugervenlig kvantificering af bakterier ved meget lave niveauer. Den endelige løsning vil rette sig mod bl.a. point?of?care applikationer i hospitaler og procesvand/sterilitetstests i farmaceutisk produktion med klar vej til industriel opskalering.